Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Other Working Capital Changes: 2012-2025

Historic Other Working Capital Changes for CorMedix (CRMD) over the last 10 years, with Sep 2025 value amounting to -$1.1 million.

  • CorMedix's Other Working Capital Changes fell 297.52% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 45.20%. This contributed to the annual value of $2.4 million for FY2024, which is 299.22% up from last year.
  • CorMedix's Other Working Capital Changes amounted to -$1.1 million in Q3 2025, which was down 140.29% from -$461,299 recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Other Working Capital Changes peaked at $2.3 million during Q1 2025, and registered a low of -$1.1 million during Q3 2025.
  • Its 3-year average for Other Working Capital Changes is $439,505, with a median of $483,526 in 2023.
  • In the last 5 years, CorMedix's Other Working Capital Changes tumbled by 2,451.75% in 2022 and then spiked by 397.35% in 2023.
  • Quarterly analysis of 5 years shows CorMedix's Other Working Capital Changes stood at -$515,918 in 2021, then spiked by 116.42% to $84,697 in 2022, then surged by 397.35% to $419,578 in 2023, then skyrocketed by 192.31% to $547,473 in 2024, then crashed by 297.52% to -$1.1 million in 2025.
  • Its Other Working Capital Changes stands at -$1.1 million for Q3 2025, versus -$461,299 for Q2 2025 and $2.3 million for Q1 2025.